CASE STUDY

COVID-19

ELIMINATING THE PATHOGEN FROM SURFACES IS EXTREMELY IMPORTANT

The COVID-19 pandemic is fast evolving and more than 175 countries across the globe continue to see more patients and community spread transmissions.

Initial review of the disease from the World Health Organization (WHO) indicates that COVID-19 has a higher transmission rate than influenza, and other coronaviruses like MERS-CoV.[1] Additionally, a recent NIH study indicates that the virus can survive for days on hard surfaces.[2]

Eliminating this deadly pathogen from surfaces is extremely important in order to allow operations to resume safely. With the high transmission rate of COVID-19 and its ability to survive on surfaces for days, facilities must work quickly and effectively to clean surfaces and eliminate the pathogen to prevent this virus from further impacting the safety of the staff and key business operations.

COVID-19 AT A SINGAPOREAN HOSPITAL

A private hospital in Singapore cared for one of the **first COVID-19 patients** in the country

The facility needed **a plan** to ensure the **ICU area** hosting the patient was **safe** for staff and future patients to occupy upon patient discharge

Bioquell's Rapid Biodecontamination Service **(RBDS)** was selected to perform enhanced disinfection on an as needed contract basis

After just **two hours** from the start of a Bioquell cycle, the hospital was able to **reopen** its **ICU**

Bioquell completed **10 separate deployments** in **less than 2 weeks** at this facility

AFTER A **TWO HOUR** BIOQUELL CYCLE, THE HOSPITAL WAS ABLE TO **REOPEN** ITS **ICU**

Bioquell RBDS may be able to **respond immediately** in your region. Visit **bioquell.com** for additional details.

1. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Mar 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
2. N van Doremalen, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. The New England Journal of Medicine. DOI: 10.1056/NEJMc2004973 (2020).

Bioquell Emerging Viral Pathogen Claim: This product qualifies for emerging viral pathogen claims per the EPA's 'Guidance to Registrants: Process for Making Claims Against Emerging Viral Pathogens not on EPA-Registered Disinfectant Labels' when used in accordance with the appropriate use of directions. Contact Bioquell for more details.

WORLDWIDE HEADQUARTER
1 Ecolab Place
St. Paul, MN 55102
USA
www.ecolab.com/lifesciences

EUROPE HEADQUARTERS
Richtistr. 7
8304 Wallisellen
Switzerland
www.ecolablifesciences.com

ECOLAB®

bioquell
An Ecolab Solution

HC001-MKT-196 - REV 2

10373.2